Hidden GLP‑1 effects

Glucagon-like peptide 1 drugs help people feel full by slowing stomach emptying and changing hunger signals, but a new 2026 study found users also report symptoms that trials did not clearly capture, including chills, hot flashes, and menstrual changes. (nature.com) The study, published April 10 in *Nature Health*, analyzed 410,198 Reddit posts from May 2019 through June 2025 and identified 67,008 users who said they had taken semaglutide or tirzepatide. Of those users, 43.5% described at least one side effect. (nature.com) The most common complaints in the paper were still familiar ones: nausea in 36.9% of posts flagged for side effects, fatigue in 16.7%, vomiting in 16.3%, constipation in 15.3%, and diarrhea in 12.6%. The newer signals were temperature-related symptoms such as chills and hot flushes, plus reproductive symptoms such as irregular periods. (nature.com) Those findings do not prove the drugs caused every symptom, because the data came from self-reports on a social platform rather than a controlled trial. The authors said social-media analysis can work as an early warning system for safety signals that formal drug monitoring may miss. (nature.com) Federal regulators have moved at the same time the market for cheaper copycat versions has expanded online. On February 6, 2026, the Food and Drug Administration said it would restrict active pharmaceutical ingredients used in non-FDA-approved compounded glucagon-like peptide 1 drugs that are mass-marketed as alternatives to approved products. (fda.gov) The FDA said companies cannot market compounded products as generic versions of approved drugs, say they use the same active ingredient, or claim they are clinically proven to deliver the same results. The agency said it could pursue seizures or injunctions if violations continue. (fda.gov) That enforcement followed another FDA step in March 2026, when the agency announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products on their websites. The FDA said compounded drugs are not FDA-approved, which means it does not review them for safety, effectiveness, or quality before sale. (fda.gov) Patients and doctors are also dealing with what happens after treatment ends. In the STEP 1 extension trial, people who stopped semaglutide regained about two-thirds of their prior weight loss within one year after coming off the drug. (pmc.ncbi.nlm.nih.gov) A later analysis of the SURMOUNT-4 tirzepatide trial found that, after an initial 36-week treatment period, most people who stopped the drug regained at least 25% of the weight they had lost within a year. Researchers also found bigger weight regain tracked with a greater reversal of cardiometabolic improvements. (jamanetwork.com) Doctors interviewed in recent coverage said that pattern is why many patients need a long-term plan for protein intake, exercise, sleep, and follow-up care before they taper off a GLP-1 drug. The drugs can reduce appetite while people build those routines, but the biology driving hunger often returns when the medication stops. (newsweek.com; pmc.ncbi.nlm.nih.gov) The picture in 2026 is less about a single miracle shot than a longer cycle of treatment, monitoring, and maintenance. As researchers surface side effects that patients talk about online and regulators tighten oversight of compounded versions, the central question is no longer just how much weight these drugs can help people lose, but how safely they are used and what happens after. (nature.com; fda.gov; pmc.ncbi.nlm.nih.gov)